Navigation Links
BD IMag Human Regulatory T Lymphocyte Separation Set for Isolation of Treg Cells

BD Biosciences is pleased to introduce the BD IMag Human Regulatory T Lymphocyte Separation Set DM (Cat. No. 558142) for the isolation of Treg cells from peripheral blood mononuclear cells (PBMC). The reagent set isolates Treg cells in two stages. First, negative selection is performed using BD IMag streptavidin particles with a cocktail of biotinylated monoclonal antibodies that recognizes antigens expressed on erythrocytes, platelets, granulocytes, monocytes, B cells, and CD8 T cells to enrich for the CD4 T lymphocytes. Then, the CD25+ CD4+ Treg cells are isolated from the enriched CD4 T lymphocytes by positive selection. This Enrichment Set has been optimized for use with the BD IMagnet, and it contains sufficient reagents to label 109 PBMC.

Please visit bdbiosciences.com/bdimag for additional information.


'"/>

Source:


Page: All 1

Related biology technology :

1. Human Primary Preadipocytes and Differentiated Adipocytes
2. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Human Universal cDNA Library Array I
6. Map and Link Human Genetic Disorders with SSLP Analysis
7. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
8. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
10. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
11. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):